Journal
DALTON TRANSACTIONS
Volume 49, Issue 47, Pages -Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0dt02715d
Keywords
-
Categories
Funding
- Guangdong Major Project of Basic and Applied Basic Research [2019B030302009]
- National Natural Science Foundation of China [21401125, 201627025, 201635031]
- Li Ka Shing Foundation Cross-Disciplinary Research Grant [2020LKSFG01F]
- Hong Kong Baptist University [RC-ICRS-18-19-01A]
- Shantou University Medical College
Ask authors/readers for more resources
The osmium(vi) nitrido complex [Os-VI(N)(sap)(py)Cl] is a potential anti-cancer drug with promising in vitro antiproliferative activities toward a panel of cancer cell lines, including cisplatin-resistant cells (IC50 values of 2.8-13.8 mu M). This drug targets DNA and changes its conformation via covalent binding and insertion. In vitro studies indicate that the drug induces HepG2 cells G2/M phase arrest, disrupts the mitochondrial membrane potential and causes caspase-mediated apoptosis. Further in vivo studies using HepG2-bearing nude mice reveal that this drug not only shows good antitumor efficacy of inhibiting tumor growth, but also does not show the side effect of weight loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available